On October 30th, the 2025 China Biotechnology Innovation Conference was held in Chengdu High tech Zone, with the gathering of 16 academicians from the Chinese Academy of Sciences and the Chinese Academy of Engineering, over 1000 experts and scholars, and the launch of major industry university research platforms. At the opening ceremony, the 2024 annual competitiveness ranking of China's biopharmaceutical industry parks was announced, with Chengdu High tech Zone ranking fourth and maintaining its position as the top tier in the country, demonstrating strong innovation vitality and regional leadership. Currently, Chengdu High tech Zone is making efforts from multiple dimensions such as policies, platforms, and finance to continuously build a biopharmaceutical innovation ecosystem, activate industrial innovation momentum, and form a full industry chain from target discovery, drug screening, clinical research to large-scale production, accelerating the construction of a globally influential and competitive biopharmaceutical innovation hub. One of the highlights of this conference is the construction of a high-energy platform. The "Global New Drug Discovery Center" established by Chengdu High tech Zone was officially unveiled at the seminar. The center will be committed to cultivating original scientific and technological achievements and leading talents, promoting collaboration between industry, academia, research and medical resources, and building a full chain hub platform from "basic research - technology development - clinical transformation - industrial landing". In the past, innovative drug research and development often faced the problem of 'data interoperability and resource dispersion'. Many pharmaceutical companies and research institutions worked alone, resulting in low research and development efficiency and high costs. The Global Center for New Drug Discovery integrates the world's largest gene coding compound library, antibody drug discovery library, and other hard core resources, and also sets up a collaborative platform that allows everyone to share data, jointly tackle problems, and directly solve the problem of 'innovation islands'. ”The relevant person in charge of Chengdu High tech Zone stated. The efforts of Chengdu High tech Zone in building an innovation platform go far beyond this. In recent years, the district has customized high-energy innovation platforms as needed and cooperated to build professional pilot platforms, further stimulating the ability of source innovation and enhancing the ability to transform achievements. A series of high-energy innovation platforms, such as the National Precision Medicine Industry Innovation Center and Tianfu Jincheng Laboratory (Frontier Medical Center), have been successively built. At the same time, batches of headquarters, platform, and pioneering projects with global influence continue to land and operate in Chengdu High tech Zone, promoting the accelerated listing of innovative achievements in biomedicine and the continuous expansion of the industry scale. In the first half of this year, the district introduced the world's leading biopharmaceutical company Takeda Pharmaceutical, China's first digital medical innovation center, and the Fortune Global 500 China Resources Group Western Innovation Center, injecting new clinical and scientific research momentum into the regional medical innovation system. As of now, Chengdu High tech Zone has gathered over 3000 biopharmaceutical enterprises, with more than 160 full lifecycle biopharmaceutical functional platforms, over 300 introduced projects, and a total investment of over 120 billion yuan. In addition to industrial and project layout, Chengdu High tech Zone continues to lead the country in policy and financial innovation, creating a favorable ecological environment for the development of the biopharmaceutical industry. In March of this year, the "Chengdu High tech Industrial Development Zone Pharmaceutical and Health Industry Circle and Strong Chain Development Policy (Revised)" was officially issued, which comprehensively supports the construction of circles and strong chains in the pharmaceutical and health industry of Chengdu High tech Industrial Development Zone from five parts: supporting participation in strategic hinterland construction, supporting innovation capability enhancement, supporting opening up to the outside world, supporting future track development, and supporting industrial ecology construction. Among them, we encourage breakthroughs in key technologies and focus on supporting cutting-edge high-level basic research and key technology breakthroughs in new targets, new sites, new mechanisms, new principles, etc. to address major clinical needs. In May, the "wutong Plan" for the medical and health industry of Chengdu Hi tech Zone was released. As the first full life cycle service list of the biomedical industry in China, the "wutong Plan" builds nine categories of professional service systems covering the full life cycle of enterprises, covering 47 service directions and 102 subdivided services, and opens up the whole chain service system from "innovative research and development - approval and registration - production transformation - product shipping". Moreover, in terms of financial innovation, Chengdu High tech Zone has formed a six in one capital support system of "funding seed angel venture capital production investment merger and acquisition", with a total of 25 pharmaceutical and health oriented funds established, with a total scale of 35.2 billion yuan. The park has also innovatively launched special financial products such as "Bio Loan", providing loan credit of nearly 1 billion yuan to more than 30 enterprises including Chengdu Haifeng Biotechnology Co., Ltd. and Sichuan Zhishan Weixin Biotechnology Co., Ltd., effectively alleviating the funding bottleneck of innovative enterprises. The reason why we came to Chengdu High tech Zone is because the policy support and financial innovation here have provided great assistance and support in the process of enterprise development, creating a unique capital ecology for enterprises, which is a competitive advantage that other parks cannot compare with. ”Dong Biao, Chairman of Sichuan Zhishan Weixin Biotechnology Co., Ltd., told reporters. In the future, Chengdu High tech Zone will continue to gather global innovation resources, promote the deep integration of industry, academia, research and application, continuously cultivate new quality productivity, and contribute more solid "Chengdu High tech Power" to the development of China's biopharmaceutical industry. (New Society)